Price T Rowe Associates Inc Uro Gen Pharma Ltd. Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Price T Rowe Associates Inc holds 12,839 shares of URGN stock, worth $136,606. This represents 0.0% of its overall portfolio holdings.
Number of Shares
12,839
Previous 10,948
17.27%
Holding current value
$136,606
Previous $184,000
10.87%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$40.3 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$39.7 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$24.5 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$23.3 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$23.2 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $242M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...